266 related articles for article (PubMed ID: 26385773)
1. Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer.
Zheng HM; Chen C; Wu XH; Chen J; Sun S; Sun JZ; Wang MW; Sun SR
Tumour Biol; 2016 Feb; 37(2):2509-18. PubMed ID: 26385773
[TBL] [Abstract][Full Text] [Related]
2. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
Zheng H; Li X; Chen C; Chen J; Sun J; Sun S; Jin L; Li J; Sun S; Wu X
Int J Nanomedicine; 2016; 11():5519-5529. PubMed ID: 27799773
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2-) subtype breast cancer by quantum-dot-based molecular imaging.
Zhu YY; Chen C; Li JJ; Sun SR
Int J Nanomedicine; 2018; 13():3795-3803. PubMed ID: 29988769
[TBL] [Abstract][Full Text] [Related]
4. Quantum dots-based in situ molecular imaging of dynamic changes of collagen IV during cancer invasion.
Fang M; Yuan JP; Peng CW; Pang DW; Li Y
Biomaterials; 2013 Nov; 34(34):8708-17. PubMed ID: 23932291
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
6. Coevolution of the tumor microenvironment revealed by quantum dot-based multiplexed imaging of hepatocellular carcinoma.
Fang M; Peng CW; Yuan JP; Zhang ZL; Pang DW; Li Y
Future Oncol; 2013 Jul; 9(7):1029-37. PubMed ID: 23837765
[TBL] [Abstract][Full Text] [Related]
7. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
Jacot W; Mollevi C; Fina F; Lopez-Crapez E; Martin PM; Colombo PE; Bibeau F; Romieu G; Lamy PJ
BMC Cancer; 2015 Dec; 15():986. PubMed ID: 26680641
[TBL] [Abstract][Full Text] [Related]
8. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
9. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
11. Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.
Lakis S; Dimoudis S; Kotoula V; Alexopoulou Z; Kostopoulos I; Koletsa T; Bobos M; Timotheadou E; Papaspirou I; Efstratiou I; Aravantinos G; Karavasilis V; Zagouri F; Gogas H; Razis E; Pentheroudakis G; Christodoulou C; Pectasides D; Fountzilas G
Anticancer Res; 2016 May; 36(5):2365-78. PubMed ID: 27127145
[TBL] [Abstract][Full Text] [Related]
12. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
Nakajima H; Ishikawa Y; Furuya M; Sano T; Ohno Y; Horiguchi J; Oyama T
Breast Cancer; 2014 Jan; 21(1):66-74. PubMed ID: 22481575
[TBL] [Abstract][Full Text] [Related]
13. Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients.
Gole L; Yeong J; Lim JCT; Ong KH; Han H; Thike AA; Poh YC; Yee S; Iqbal J; Hong W; Lee B; Yu W; Tan PH
Breast Cancer Res; 2020 May; 22(1):42. PubMed ID: 32375854
[TBL] [Abstract][Full Text] [Related]
14. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
15. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number.
Sobande F; Dušek L; Matějková A; Rozkoš T; Laco J; Ryška A
Cesk Patol; 2015; 51(2):80-6. PubMed ID: 25970719
[TBL] [Abstract][Full Text] [Related]
16. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Yip C; Foidart P; Somja J; Truong A; Lienard M; Feyereisen E; Schroeder H; Gofflot S; Donneau AF; Collignon J; Delvenne P; Sounni NE; Jerusalem G; Noël A
Br J Cancer; 2017 Mar; 116(6):742-751. PubMed ID: 28196064
[TBL] [Abstract][Full Text] [Related]
17. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
18. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.
Levva S; Kotoula V; Kostopoulos I; Manousou K; Papadimitriou C; Papadopoulou K; Lakis S; Koukoulias K; Karavasilis V; Pentheroudakis G; Balassi E; Zagouri F; Kaklamanos IG; Pectasides D; Razis E; Aravantinos G; Papakostas P; Bafaloukos D; Rallis G; Gogas H; Fountzilas G
Cancer Genomics Proteomics; 2017; 14(3):181-195. PubMed ID: 28446533
[TBL] [Abstract][Full Text] [Related]
20. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
